We are committed to the discovery, development and
commercialization of first-in-class treatments for
cancer and immune-inflammatory diseases

Leveraging the body’s
natural elements

VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements.

VTS Platform for cancer
Lecinoxoid Platform for inflammation

Promising therapies

Our lead candidates are VB-111 for solid tumor indications, and  VB-201, an oral small molecule, which modulates the body’s inflammatory response.

GBM
Thyroid
Additional

Psoriasis
Ulcerative colitis